Background: SBA is a rare tumour which carries a poor prognosis. Very few data on prognostic factors and\ntreatment outcomes are available. We conducted a retrospective analysis of patients treated for SBA at our\ninstitution.\nMethods: Clinico-pathological characteristics, treatments and outcomes of all the SBA patients treated consecutively\nfrom 1996 to 2011 were retrospectively collected. The prognostic value of baseline factors was assessed using the Cox\nregression model. The Kaplan-Meier method was used to estimate the survival outcomes.\nResults: Eighty-four patients with SBA were treated during the study period. Of these, 48 presented with early stage\nSBA, while 36 had unresectable disease. All early stage SBA patients (58.3% males; median age, 59 years) underwent\nresection (R0 in 44/48) and 27 (56%) received adjuvant chemotherapy. Median relapse-free survival and overall survival\n(OS) were 31.1 months (95% CI: 8.0-54.3) and 42.9 (95% CI: 0ââ?¬â??94.9), respectively. In univariate analyses, poor histological\ndifferentiation (p = 0.025) and lymphovascular invasion (p = 0.003) were prognostic for OS. In the group of patients with\nrelapsed, unresectable or metastatic disease (n = 59), systemic chemotherapy was administered in 46 cases (78%). The\nresponse rate to first line chemotherapy was 50%. Median progression-free survival and OS were 8.8 (95% CI: 5.5-12.3)\nand 12.8 months (95% CI: 8.4-17.2), respectively. In univariate analyses, low albumin (p = 0.041) and high platelet count\n(p = 0.007) were prognostic for OS.
Loading....